Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Not Confirmed
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Not Confirmed
Not Confirmed
17-19 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BePharma
Not Confirmed
Contact SupplierBePharma
Industry Trade Show
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Industry Trade Show
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Industry Trade Show
Not Confirmed
17-19 March, 2026
Digital content
NEWS #PharmaBuzz
11 Feb 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/bausch-health-announces-2026-gastrointestinal-health-scholars-program-302682672.html
07 Jul 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bausch-healths-gastroenterology-business-salix-pharmaceuticals-launch-1044901
06 May 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/xifaxanr-rifaximin-treatment-following-overt-hepatic-encephalopathy-o-1023754
17 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/us-district-court-grants-summary-judgment-in-favor-of-fda-salix-and-t-1016430
10 Feb 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bausch-health-announces-2025-salix-gastrointestinal-health-scholars-pr-981885
05 Dec 2024
// ACCESSWIRE
https://www.accesswire.com/949208/bausch-health-and-salix-in-collaboration-with-health-organizations-recognize-the-second-annual-opioid-induced-constipation-oic-awareness-day
Drugs in Development
Details:
Relistor (methylnaltrexone bromide) is an opioid antagonist, its subcutaneous formulation is being investigated in patients with resectable head and neck squamous cell carcinoma.
Lead Product(s): Naltrexone Methobromide
Therapeutic Area: Oncology Brand Name: Relistor
Study Phase: Phase IVProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2024
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Salix Announces Phase 2 Study of RELISTOR® in Resectable HNSCC
Details : Relistor (methylnaltrexone bromide) is an opioid antagonist, its subcutaneous formulation is being investigated in patients with resectable head and neck squamous cell carcinoma.
Product Name : Relistor
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 06, 2024
Details:
RELISTOR (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Lead Product(s): Naltrexone Methobromide
Therapeutic Area: Gastroenterology Brand Name: Relistor
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Bausch Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 24, 2022
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RELISTOR (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Product Name : Relistor
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 24, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Neurology Brand Name: Xifaxan
Study Phase: Approved FDFProduct Type: Antibiotic
Recipient: Bausch Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 28, 2022
Lead Product(s) : Rifaximin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
Details : XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Product Name : Xifaxan
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 28, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Neurology Brand Name: Xifaxan
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Bausch Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 20, 2022
Lead Product(s) : Rifaximin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver...
Details : XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Product Name : Xifaxan
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 20, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Neurology Brand Name: Xifaxan
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Bausch Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 18, 2022
Lead Product(s) : Rifaximin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022
Details : XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Product Name : Xifaxan
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 18, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Neurology Brand Name: Xifaxan
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2022
Lead Product(s) : Rifaximin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Product Name : Xifaxan
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 07, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Neurology Brand Name: Xifaxan
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Bausch Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 25, 2021
Lead Product(s) : Rifaximin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific M...
Details : XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Product Name : Xifaxan
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 25, 2021
Details:
RELISTOR® (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Lead Product(s): Naltrexone Methobromide
Therapeutic Area: Gastroenterology Brand Name: Relistor
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2021
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At The American Society For Pain Manag...
Details : RELISTOR® (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Product Name : Relistor
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 28, 2021
Details:
The three abstracts presented at PAINWeek represent the broad utilization of RELISTOR in the various settings of care in which OIC patients visit.
Lead Product(s): Naltrexone Methobromide
Therapeutic Area: Gastroenterology Brand Name: Relistor
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Bausch Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 02, 2021
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021
Details : The three abstracts presented at PAINWeek represent the broad utilization of RELISTOR in the various settings of care in which OIC patients visit.
Product Name : Relistor
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 02, 2021
Details:
TRULANCE® (plecanatide) is a guanylate cyclase-C (GC-C) agonist, indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).
Lead Product(s): Plecanatide
Therapeutic Area: Gastroenterology Brand Name: Trulance
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 15, 2021
Lead Product(s) : Plecanatide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Salix Will Share TRULANCE (Plecanatide) Data At The 2021 AANP National Conference
Details : TRULANCE® (plecanatide) is a guanylate cyclase-C (GC-C) agonist, indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).
Product Name : Trulance
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Inspections and registrations
ABOUT THIS PAGE
Share 
